Canada · Delayed Price · Currency is CAD NurExone Biologic Statistics
Total Valuation
TSXV:NRX has a market cap or net worth of CAD 63.48 million. The enterprise value is 62.22 million.
| Market Cap | 63.48M |
| Enterprise Value | 62.22M |
Important Dates
The last earnings date was Friday, November 28, 2025.
| Earnings Date | Nov 28, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
TSXV:NRX has 90.68 million shares outstanding. The number of shares has increased by 27.20% in one year.
| Current Share Class | 90.68M |
| Shares Outstanding | 90.68M |
| Shares Change (YoY) | +27.20% |
| Shares Change (QoQ) | +2.05% |
| Owned by Insiders (%) | 5.16% |
| Owned by Institutions (%) | n/a |
| Float | 86.00M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | 31.28 |
| P/TBV Ratio | 31.28 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -6.84 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -8.65 |
Financial Position
The company has a current ratio of 1.33, with a Debt / Equity ratio of 0.05.
| Current Ratio | 1.33 |
| Quick Ratio | 1.28 |
| Debt / Equity | 0.05 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.02 |
| Interest Coverage | -109.69 |
Financial Efficiency
Return on equity (ROE) is -298.06% and return on invested capital (ROIC) is -179.98%.
| Return on Equity (ROE) | -298.06% |
| Return on Assets (ROA) | -129.23% |
| Return on Invested Capital (ROIC) | -179.98% |
| Return on Capital Employed (ROCE) | -362.78% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
| Beta (5Y) | 0.23 |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 0.81 |
| 200-Day Moving Average | 0.73 |
| Relative Strength Index (RSI) | 40.79 |
| Average Volume (20 Days) | 32,684 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -9.01M |
| Pretax Income | -9.10M |
| Net Income | -9.10M |
| EBITDA | -8.81M |
| EBIT | -9.01M |
| Earnings Per Share (EPS) | -0.12 |
Balance Sheet
The company has 1.37 million in cash and 110,038 in debt, giving a net cash position of 1.26 million or 0.01 per share.
| Cash & Cash Equivalents | 1.37M |
| Total Debt | 110,038 |
| Net Cash | 1.26M |
| Net Cash Per Share | 0.01 |
| Equity (Book Value) | 2.03M |
| Book Value Per Share | 0.02 |
| Working Capital | 395,581 |
Cash Flow
In the last 12 months, operating cash flow was -7.06 million and capital expenditures -128,146, giving a free cash flow of -7.19 million.
| Operating Cash Flow | -7.06M |
| Capital Expenditures | -128,146 |
| Free Cash Flow | -7.19M |
| FCF Per Share | -0.08 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
TSXV:NRX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -27.20% |
| Shareholder Yield | -27.20% |
| Earnings Yield | -14.34% |
| FCF Yield | -11.33% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |